Sulfafurazole
Chemical compound
- To be avoided within two months of term
administration
- J01EB05 (WHO) S01AB02 (WHO) QJ01EQ05 (WHO)
- In general: ℞ (Prescription only)
- 4-Amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
- 127-69-5
Y
- 5344
- DB00263
N
- 5151
- 740T4C525W
- D00450 Y
- ChEMBL453 N
- DTXSID6021292
- Interactive image
- CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
- InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
- Key:NHUHCSRWZMLRLA-UHFFFAOYSA-N
N
Y (what is this?) (verify)Sulfafurazole (INN, also known as sulfisoxazole) is a sulfonamide antibacterial with an dimethyl-isoxazole substituent. It possesses antibiotic activity against a wide range of Gram-negative and Gram-positive organisms.[1] It is sometimes given in combination with erythromycin (see erythromycin/Sulfafurazole) or phenazopyridine. It is used locally in a 4% solution or ointment.
References
- ^ Holmes NE, Grauson ML (October 2017). "Sulfonamides". In Paterson DL, McCarthy JS, Mouton JW, Mills J, Grayson ML, Cosgrove SE, Crowe S, Hope W (eds.). Kucers' The Use of Antibiotics (7th ed.). CRC Press. pp. 1571–1624. ISBN 978-1-4987-4796-7.
External links
- Sulfisoxazole at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- MedlinePlus DrugInfo medmaster-a601049
- MedlinePlus DrugInfo medmaster-a601115
- Diseases Database (DDB): 30455
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
| DHFR inhibitor | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sulfonamides (DHPS inhibitor) |
| ||||||||
| Combinations |
| ||||||||
| Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
| 1st generation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolones |
| ||||||||
| Newer non-fluorinated | |||||||||
| Related (DG) |
inhibitors
| Nitroimidazole derivatives | |
|---|---|
| Nitrofuran derivatives |
| Rifamycins/ RNA polymerase | |
|---|---|
| Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
